Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Umbilical Cord Blood for ASD
NCT02176317Phase 1Completed
- Sponsor
- Duke University
- Start
- Jun 2014
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous umbilical cord blood reinfusion in Autism Spectrum Disorder (ASD), sponsored by Duke University. Primary endpoint: Number of participants with non-serious and serious adverse events at 12 months. Started Jun 2014; status: completed.
02
Drugs
autologous umbilical cord blood reinfusion
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02176317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176317.